Rosamines targeting the cancer oxidative phosphorylation pathway

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lim, Siang Hui ^a,b   Wu, Liangxing ^c   Kiew, Lik Voon ^b   Chung, Lip Yong ^b   Burgess, Kevin ^c   Lee, Hong Boon ^a  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMOBENZENE ROSAMINE; 4 CHLOROBENZENE ROSAMINE; 4 IODOPHENYL ROSAMINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; FURAN ROSAMINE; NSC 751817; NSC 751819; ROSAMINE DERIVATIVE; SUCCINATE DEHYDROGENASE (UBIQUINONE); THIOFURYL ROSAMINE; UNCLASSIFIED DRUG; AMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR GROWTH; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; TUMOR CELL LINE;

AMINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; OXIDATIVE PHOSPHORYLATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898003999     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082934     Document Type: Article

References (32)

1. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
2. Nahta R, Esteva FJ (2007) Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643. (Pubitemid 46842713)
3. Alcala AM, Flaherty KT (2012) BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 18: 33-39.
4. Ayoola A, Barochia A, Belani K, Belani CP (2012) Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30: 433-446.
5. McBride HM, Neuspiel M, Wasiak S (2006) Mitochondria: more than just a powerhouse. Curr Biol 16: R551-560. (Pubitemid 44066793)
6. Biasutto L, Dong LF, Zoratti M, Neuzil J (2010) Mitochondrially targeted anticancer agents. Mitochondrion 10: 670-681.
7. Wang F, Ogasawara MA, Huang P (2010) Small mitochondria-targeting molecules as anti-cancer agents. Molecular Aspects of Medicine 31: 75-92.
8. Modica-Napolitano JS, Aprille JR (2001) Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49: 63-70. (Pubitemid 32493800)
9. Lampidis TJ, Hasin Y, Weiss MJ, Chen LB (1985) Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother 39: 220-226. (Pubitemid 16194118)
10. Lim SH, Wu L, Burgess K, Lee HB (2009) New cytotoxic rosamine derivatives selectively accumulate in the mitochondria of cancer cells. Anticancer Drugs 20: 461-468.
11. Wu L, Burgess K (2008) Synthesis and spectroscopic properties of rosamines with cyclic amine substituents. J Org Chem 73: 8711-8718.
12. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, et al. (1980) Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 26: 127-132. (Pubitemid 10086410)
13. Boyd MR, Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109.
14. Frezza C, Cipolat S, Scorrano L (2007) Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2: 287-295. (Pubitemid 47040043)
15. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y (2007) Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 21: 902-911. (Pubitemid 46603229)
16. Reers M, Smith TW, Chen LB (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30: 4480-4486.
17. Jin W, Kim GM, Kim MS, Lim MH, Yun C, et al. (2010) TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 31: 1939-1947.
18. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L, Alley MC (1997) Human tumor xenograft models. In: Teicher B, editor. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ: Humana Press. pp. 101-125.
19. Hollingshead MG (2008) Antitumor efficacy testing in rodents. J Natl Cancer Inst 100: 1500-1510.
20. Gerebtzoff G, Li-Blatter X, Fischer H, Frentzel A, Seelig A (2004) Halogenation of drugs enhances membrane binding and permeation. Chembiochem 5: 676-684. (Pubitemid 39257090)
21. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
22. Moreno SN, Gadelha FR, Docampo R (1988) Crystal violet as an uncoupler of oxidative phosphorylation in rat liver mitochondria. J Biol Chem 263: 12493-12499. (Pubitemid 19000431)
23. Kowaltowski AJ, Turin J, Indig GL, Vercesi AE (1999) Mitochondrial effects of triarylmethane dyes. J Bioenerg Biomembr 31: 581-590. (Pubitemid 30082901)
24. Toogood PL (2008) Mitochondrial drugs. Curr Opin Chem Biol 12: 457-463.
25. Don AS, Hogg PJ (2004) Mitochondria as cancer drug targets. Trends Mol Med 10: 372-378. (Pubitemid 39061138)
26. Modica-Napolitano JS, Weiss MJ, Chen LB, Aprille JR (1984) Rhodamine 123 inhibits bioenergetic function in isolated rat liver mitochondria. Biochem Biophys Res Commun 118: 717-723.
27. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
28. Renda F, Mura P, Finco G, Ferrazin F, Pani L, et al. (2013) Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Oharmaco Sci 17 45-49.
29. Kraut JA, Madias NE (2012) Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol 8: 589-601.
30. Kurtoglu M, Lampidis TJ (2009) From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Mol Nutr Food Res 53: 68-75.
31. Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al. (2009) Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging. Clin Nucl Med 34: 762-767.
32. Kesterson JP, Odunsi K, Lele S (2010) High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy 56: 108-111.